The majority of the studies reported a high burden of work-related outcomes among inflammatory bowel disease patients regardless of the methodology used .
Inflammatory bowel disease patients experience a high burden in work-related outcomes .
BACKGROUND & AIMS Inflammatory bowel disease has considerable effects on work-related outcomes and leads to high societal costs due to sick leave and disability pension .
The aims of this study were to systematic ally review evidence on work-related outcomes that are relevant to productivity losses and to evaluate whether medical or surgical interventions have a positive impact on patients ' work ability .
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
BACKGROUND AND AIMS Crohn 's disease negatively affects patients '  quality of life and ability to work . We investigated the impact of adalimumab on work productivity , daily activities , and quality of life in an open-label trial ( N=945 ) . The population comprised both infliximab-naïve and -exposed patients , including infliximab primary non-responders . METHODS Patients received adalimumab induction therapy ( 160 mg/80 mg at Weeks 0/2 ) , followed by adalimumab 40 mg every other week for up to 20 weeks ( patients with flares/non-response could receive 40 mg weekly at/after Week 12 ) . The Work Productivity and Activity Impairment Question naire and Short Inflammatory Bowel Disease Question naire were assessed . Indirect cost savings were estimated based on the average work productivity improvements at Week 20 . RESULTS Mean baseline scores indicated severe productivity impairment and poor quality of life . At Week 20 , 60 % of infliximab-naïve and 47 % of infliximab primary non-responders achieved clinical ly important improvements ( ≥9 points ) on the Short Inflammatory Bowel Disease Question naire , and 51 % and 43 % , respectively , achieved the minimum clinical ly important difference ( improvement ≥7 percentage points ) for total work productivity impairment ( non-responder imputation ) . At Week 20 , 64 % of infliximab-naïve and 55 % of infliximab primary non-responders achieved clinical ly important improvements in total activity impairment . Estimated 20-week total indirect productivity-related cost savings were € 3070 per infliximab-naïve patient and € 2059 per infliximab-exposed patient . CONCLUSIONS Adalimumab therapy significantly improved work productivity and disease-specific quality of life for patients with moderate to severe Crohn 's disease . Patients who failed prior infliximab therapy and patients naïve to infliximab benefited from adalimumab , with potentially greater benefits for  infliximab-naïve patients ( NCT00409617 )
The majority of the studies reported a high burden of work-related outcomes among inflammatory bowel disease patients regardless of the methodology used .
Inflammatory bowel disease patients experience a high burden in work-related outcomes .
BACKGROUND & AIMS Inflammatory bowel disease has considerable effects on work-related outcomes and leads to high societal costs due to sick leave and disability pension .
The aims of this study were to systematic ally review evidence on work-related outcomes that are relevant to productivity losses and to evaluate whether medical or surgical interventions have a positive impact on patients ' work ability .